COIOSDeep risk insights through multi-disciplinary research across the globe
Euro wallet, tablet with chart, and coins on wooden table
Item refines Peer-reviewed Added

Oncological liquid biopsy is cost-effective in most modelled scenarios across thresholds

Median incremental net monetary benefit of liquid biopsy in cancer was positive at all eight willingness-to-pay thresholds tested, across 43 modelled scenarios from 21 economic evaluations.

This systematic review re-analysed 43 modelled scenarios from 21 economic evaluations of liquid biopsy in cancer. Costs were harmonised to 2024 euros, and net monetary benefit was recalculated under eight willingness-to-pay thresholds. Median net benefit was positive under all eight, ranging from €79.52 to €5,091.21 per patient. Under a common threshold of twice Italian GDP per capita, the median was €1,560.07 per patient. Eight scenarios were dominant, while 17 (39.5%) changed classification across thresholds. Scenarios differed in pathways, assumptions and local costs, were not independent, and lacked patient-level data.

Why it is interesting: The same modelled costs and QALYs can look cost-effective or not, depending only on the threshold chosen. Two cost-saving scenarios lowered health, which a positive net benefit alone does not reveal.

Source
The Journal of Liquid Biopsy, 16 November 2026
Paper
Is liquid biopsy in oncology cost-effective? A comparative analysis and systematic review
Authors
Gottardo A, Galvano A, Bazan Russo TD, Busuito G, Di Marco E, Zanatta P et al.
DOI
10.1016/j.jlb.2026.100690
Full text
Open copy (open-access copy, PubMed Central)
Type
Peer-reviewed article
Design
Systematic review and harmonised comparative re-analysis of economic evaluations; 21 studies, 43 modelled scenarios, costs standardised to EUR 2024, INMB recalculated under eight WTP criteria
Verdict
Refines prior evidence
Driver
Value in health

Other drivers in Data, models and systems